Posted by Michael Wonder on 29 May 2023
Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the EU
26 May 2023 - Regulatory processes are continuing in other countries including the US.
Ipsen announced today that the re-examination of palovarotene as a potential treatment for the ultra-rare bone disease, fibrodysplasia ossificans progressiva, by the CHMP of the EMA confirms the negative opinion given in January 2023.
